No Detail Found!

Intravenous Alteplase Treatment of Acute Ischemic Stroke Patients Exhibiting Mild Neurological De cits

Author(s)
Jing Sun Department of Neurology, Lanzhou University Second Hospital,Lanzhou, Gansu,China
Hongxia Wang Department of Neurology, Lanzhou University Second Hospital,Lanzhou, Gansu,China
Mengjiao Sun Department of Neurology, Lanzhou University Second Hospital,Lanzhou, Gansu,China
Qinfang Xie Department of Neurology, Lanzhou University Second Hospital,Lanzhou, Gansu,China
Ning Liu Department of Neurology, Lanzhou University Second Hospital,Lanzhou, Gansu,China
Manxia Wang Department of Neurology, Lanzhou University Second Hospital,Lanzhou, Gansu,China
Abstract
Alteplase is increasingly used for treating ischemic stroke cases with low NIHSS scores, but the guidelines and evidence regarding outcomes are lacking. So, the authors conducted an updated meta-analysis to better understand the e ects of alteplase for the treatment of acute mild ischemic stroke. PubMed, Cochrane, EMBASE were systematically explored for all relevant investigations published as in September 2021. Study quality was assessed as per the Cochrane system criteria, and Stata 15.1 was utilised to carry out a meta-analysis. In total, 16 trials incorporating 5,846 patients were analysed (1,926 and 3,920 cases in the rt-PA and non-thrombolytic groups, respectively). The main outcome measure revealed that the treatment of rt-PA was correlated with better odds of a modi ed Rankin Scale (mRS) score of 0-1 relating to the non-thrombolytic group (OR = 1.12, 95% CI = 1.02-1.23, p <0.05), and with moderate heterogeneity (2I = 0.0%, p = 0.930). For the secondary study outcomes, symptomatic intracranial hemorrhage incidence was 4.46 times greater in the group of rt-PA, relating to the nonthrombolytic group (OR =4.46, 95% CI = 27.5-7.23, p <0.001). There were no considerable di erences in the mortality between the two groups (OR = 0.46, 95% CI = 0.39-10.3, p >0.05). No signi cant heterogeneity was detected in secondary study outcomes. Subgroup analysis showed that the function outcomes was the best within 3-4.5 hour;sand the risk and mortality of sICH were the lowest within 3-4.5 hours. Intravenous rt-PA administration is associated with improved functional outcomes at three months after the stroke in mild ischemic stroke patients.
Publication Details
Page(s) 352-358
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Meta-analysis, Acute Ischemic Stroke, mild, Alteplase
0

Citations

0

Downloads

63

Views